alexa Exhaled Nitric Oxide Measurement may Predict Asthma Exa
ISSN: 2155-6121

Journal of Allergy & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Exhaled Nitric Oxide Measurement may Predict Asthma Exacerbation after Stepping down Formoterol/Budesonide Combination Therapy in Adult Asthma

Toshihiro Shirai*, Tomotaka Kawayama, Hiroyuki Nagase, Hiromasa Inoue, Suguru Sato, Koichiro Asano and Hiroaki Kume

Early Biomarker for Treatment Study Group, Innovative Asthma Association, Japan

*Corresponding Author:
Toshihiro Shirai
Department of Respiratory Medicine, Shizuoka General Hospital
4-27-1 Kita-Ando, Aoi, Shizuoka, 420-8527 Japan
Tel: 81-54-247-6111
Fax: 81-54-247-6140
E-mail: [email protected]

Received date: April 01, 2013; Accepted date: May 15, 2014; Published date: May 20, 2014

Citation: Shirai T, Kawayama T, Nagase H, Inoue H, Sato S, et al. (2014) Exhaled Nitric Oxide Measurement may Predict Asthma Exacerbation after Stepping down Formoterol/Budesonide Combination Therapy in Adult Asthma. J Allergy Ther 5:173. doi: 10.4172/2155-6121.1000173

Copyright: © 2014 Shirai T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objective: The Global Initiative for Asthma (GINA) guidelines state that when asthma control is maintained for at least 3 months, treatment can be stepped down; however, prediction tools have not been established for the reappearance of symptoms and increased risk of exacerbation on stepping down treatment. This study was designed to assess whether FeNO measurement predicts asthma exacerbation after stepping down from fixed dose formoterol/budesonide combination (FBC)9/320 μg bid to 4.5/160 μg bid (UMIN000005406).

Methods: Subjects included 37 patients receiving a fixed-dose FBC 9/320 μg bid for at least 3 months, and achieving controlled asthma (GINA) in conjunction with an Asthma Control Questionnaire (5-item version (ACQ5) score ≤ 0.75). Based on the FeNO value at stepping down, patients were classified into 25 patients with FeNO<37 ppb and 12 with FeNO ≥ 37 ppb. The primary endpoint was the occurrence of asthma exacerbation within 8 weeks and from 8 weeks until 12 months. Secondary endpoints, including ACQ5, FeNO, and pulmonary function tests, were measured at baseline and until 8 weeks.

Results: There was no difference in the incidence of exacerbation between patients with FeNO ≥ 37 ppb and those with FeNO<37 ppb within 8 weeks; however, in a long-term follow up until 12 months, the incidence was significantly higher in patients with FeNO ≥ 37 ppb than in those with FeNO<37 ppb (odds ratio 11.33, 95% confidence interval 1.45 to 88.52).There was no statistically significant differencein changes in ACQ5, pulmonary functions, and FeNO between the 2 groups by 2-way repeated measures analysis of variance.

Conclusions: Higher FeNO levels may predict asthma exacerbation not within a short period of time, but in a long-term follow-up after stepping down FBC therapy in adult asthma.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords